Lexicon Pharmaceuticals LXRX Business Segments — Other Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherExpenses.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's business segments — other expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's business segments — other expenses?
- Lexicon Pharmaceuticals (LXRX) reported business segments — other expenses of $1.59M in Q1 2026.
- How has Lexicon Pharmaceuticals's business segments — other expenses changed year-over-year?
- Lexicon Pharmaceuticals's business segments — other expenses decreased by 13.4% year-over-year, from $1.84M to $1.59M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — other expenses?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — other expenses has grown at a 44.2% compound annual growth rate (CAGR), from $2.78M to $8.34M.
- What does business segments — other expenses mean?
- Non-operating costs or peripheral financial charges that impact the segment's net financial position, such as interest expense or foreign exchange losses. These items are distinct from core operational costs and provide insight into the segment's financial leverage and external risk exposure. Monitoring these helps isolate the impact of non-core activities on the segment's bottom line.